Doug Ingram, Sarepta CEO (Sarepta Therapeutics)
Sarepta CEO Doug Ingram pins gene therapy delay on Covid-burdened FDA, can't offer timeline for fix
There are few dull days when it comes to Sarepta and the FDA.
The muscular dystrophy-focused biotech, whose back-and-forth travails with the agency have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
